Publisher Correction: Viral fibrotic scoring and drug screen based on MAPK activity uncovers EGFR as a key regulator of COVID-19 fibrosis
Guardado en:
Autores principales: | Elmira R. Vagapova, Timofey D. Lebedev, Vladimir S. Prassolov |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/29bbb599cea84f50b7afcfcbd775548f |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Viral fibrotic scoring and drug screen based on MAPK activity uncovers EGFR as a key regulator of COVID-19 fibrosis
por: Elmira R. Vagapova, et al.
Publicado: (2021) -
Fibrotic microtissue array to predict anti-fibrosis drug efficacy
por: Mohammadnabi Asmani, et al.
Publicado: (2018) -
Favorable Immune Microenvironment in Patients with EGFR and MAPK Co-Mutations
por: Yang W, et al.
Publicado: (2020) -
A Cell-Based Platform for the Investigation of Immunoproteasome Subunit β5i Expression and Biology of β5i-Containing Proteasomes
por: Alexander Burov, et al.
Publicado: (2021) -
A model of human lung fibrogenesis for the assessment of anti-fibrotic strategies in idiopathic pulmonary fibrosis
por: Katy M. Roach, et al.
Publicado: (2018)